Current amyloid models offer no way to direct transgenic APP to specific cell types for studies that might need this specificity, such as a comparison of APP processing in excitatory versus inhibitory neurons, or assessment of amyloid formation by layer 2/3 versus layer 5 pyramidal neurons. The gene discussed is APP; the disease is amyloidosis.